Vanishing White Matter Disease Clinical Trial
Official title:
A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy Following ABBV-CLS-7262 Administration in Adult and Pediatric Subjects With Vanishing White Matter Disease
ABBV-CLS-7262 is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult and pediatric subjects. This is a 96-week, open-label, multiple cohort study enrolling adults and pediatric subjects with Vanishing White Matter disease who are 6 years or older. Subjects will attend regular visits during the course of the study and complete medical assessments, blood tests, checking for side effects, and completing questionnaires.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
| Recruiting |
NCT03333200 -
Longitudinal Study of Neurodegenerative Disorders
|
||
| Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|